Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
1. MHRA supports ART12.11's FIH study design and nonclinical development plan. 2. ART12.11 may qualify for accelerated development via Innovative Licensing and Access Pathway. 3. Positive preclinical results show ART12.11's efficacy comparable to leading antidepressants. 4. Regulatory assurance could reduce costs for ART12.11's development program significantly. 5. Potential for longer market exclusivity with patents valid until 2038.